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The decision made in the year 2004 by the U.S. Food and Drug Administration (FDA) to 
require a boxed warning on antidepressants regarding the risk of suicidality in young adults 
still represents a matter of controversy. The FDA warning was grounded on industry-
sponsored trials carried one decade ago or earlier. However, within the past decade, 
an increasing number of reports have questioned the actual validity of the FDA warning, 
especially considering a decline in the prescription of the antidepressant drugs associated 
with an increase in the rate of suicidal events among people with severe depression. The 
present report provides an overview of the FDA black box warning, also documenting 
two Major Depressive Disorder patients whose refusal to undergo a pharmacological 
antidepressant treatment possibly led to an increased risk for suicidal behaviors. The 
concerns raised by the FDA black box warning need to be considered in real-world 
clinical practice, stating the associated clinical and public health implications.
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INTRODUCTION
Suicidal behavior (herein including completed suicide and non-fatal suicide attempts) accounts 
for remarkably high rates of mortality and morbidity worldwide. The World Health Organization 
(WHO) estimates that 800,000–1,000,000 individuals died by suicide in the year 2000, making it the 
13th leading cause of death that year (1).
Suicide may occur within the course of Severe Mental Illnesses (SMIs) such as Major Depressive 
Disorder (MDD), Bipolar Disorder (BD), or schizophrenia, as well as other conditions. Contributory 
factors for increased suicide risk include the presence of anxiety, personality and substance use 
disorders, severe neuropsychiatric disorders and head injury, inherent genetic factors, clinical 
psychological factors, aggression and impulsivity, hopelessness, history of childhood abuse, adverse 
life events and psychosocial stressors, just to name few (2, 3).
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Suicide may occur as part of the natural course of SMIs, or it 
may occur due to improper treatment of severe depression (4, 5).
While sub-optimal dosage of the antidepressant drug (or 
exposure to the physical and psychosocial treatment) may 
intuitively represent inadequate treatment of depression 
(inflating the risk for suicidality), the operational definition of 
optimal treatment of depression remains elusive (4).
Several reports highlighted the risk associated with 
antidepressant drug monotherapy in BD (6–8). However, 
the corresponding evidence for MDD is not that compelling, 
especially beyond the acute treatment phase of unipolar 
depression (9).
Based on anecdotal reports suggesting an inflated rates of suicidal 
behavior among MDD patients exposed to the Selective Serotonin 
Reuptake Inhibitors (SSRIs) (10), beginning from October 2003, the 
U.S. Food and Drug Administration (FDA) issued a series of health 
advisories and warnings for children and adolescents prescribed 
with antidepressant drugs (11). Such a claim was supported by a 
subsequent, controversial meta-analytic report of industry-sponsored 
trials on pediatric patients (12). Notably, the analysis—carried out 
by the FDA on controlled clinical trials encompassing 2,200 children 
exposed to any of the nine FDA-approved antidepressants commonly 
prescribed at the time—could not highlight an overall difference in 
terms of suicide risk with antidepressants vs. placebo. Such analysis 
could not even highlight any difference across the appraised SSRIs 
or other types of antidepressants vs. placebo (13). Indeed, the 
FDA-conducted meta-analyses of 372 randomized clinical trials 
of antidepressants involving nearly 100,000 participants, which 
showed that rates of suicidal thinking or behavior was higher among 
patients assigned to antidepressants when compared with placebo, 
and in a subsequent age-stratified analysis it was shown that such 
increased risk was significant only among children and adolescents 
under the age of 18 years. There was no evidence of increased risk 
among adults older than 24 years, and, among adults 65 years of age 
or older, antidepressants had an apparent protective effect against 
the development of suicidal ideation and behavior. The meta-
analysis performed by the FDA had some methodological issues. 
For example, the assessment of suicide in the trials included in the 
pooled analysis is questionable from a validity standpoint, since the 
appraised trials were not primarily designed to assess suicidality as 
the primary outcome prospectively.
Moreover, how the risk of an event is measured has significant 
implications. The fact that antidepressants increase the risk of 
suicide in people younger than 18 years old holds true. However, 
how this risk is presented affects the perception of the prescribing 
clinicians (and possibly the attitude of the patients handling the 
antidepressant booklet). When the risk of suicidality is defined 
in absolute terms, the impact is negligible; however, when it is 
defined in relative terms, using a measure such the odd ratio 
(OR), the risk seems to be magnified.
On October 2004, the FDA required a so-called black box 
warning for antidepressant drugs of any class. That warning 
became effective in January 2005. In 2006, the FDA warning 
extended to young adults aged up to 25 years, an announcement 
that followed a slew of media reports about the link between 
antidepressant drug use and suicide, possibly culminating in an 
exaggerated alarmist message (14).
The FDA black box warning on antidepressant-linked 
suicide in young people has been questioned (15), and recent 
evidence on the overall benefits from the use of antidepressants 
in the treatment of MDD seems not to be so pessimistic (16). 
Major concerns about the actual validity of the FDA black box 
warning by independent clinical researchers has accumulated 
over recent years, with some experts fearing that the “black 
box warning would be the final step before prohibiting the use of 
medication” (17).
The over-concern raised by the FDA most likely proved to be 
effective in decreasing the prescription of effective medications. 
The rates of antidepressant drug prescriptions declined nearly 
50%, especially in children and adolescents (18). The rate of the 
diagnosis of MDD reduced almost 40% (19), possibly due also 
to the diagnostic shift in favor of BD within the past decade 
and the availability of the second-generation antipsychotics, 
SGAs, besides the regulatory issues. The anticipated increase 
in the use of face-to-face psychotherapy to treat depression 
and prevent suicide expected by the FDA did not occur (14, 
19). On the contrary, the utilization rates of psychoactive drugs 
such as benzodiazepines, and antipsychotics increased over the 
time following the FDA black box warning, especially among 
young females (15). However, it is worth noticing that even if 
suicide or some other adverse outcome had worsened in 2005 
onward, coincident with a decline in antidepressant use, it would 
not necessarily mean that the two phenomena were connected 
to each other (20). Despite the increasing body of evidence 
contrasting the strict regulatory rules enforced by the FDA, the 
agency seems reluctant to retract the black box warning (14), 
even if that claim may rely on miscalculations, or it may not 
fit the real-world practice, as documented in the case reports 
outlined in the following lines.
CASE REPORTS
Patient n.1
Mrs. A. is a 24-year-old married Caucasian woman denying any 
personal or familial history for psychiatric disorders or other 
medical conditions.
On May 2014, Mrs. A. reported intense psychological and 
physical discomfort for the first time in her life, beginning soon 
after she lost her job, and she experienced significant financial 
problems. The patient sought professional support by a private 
practice psychiatrist, who prescribed the following: escitalopram 
up to 15 mg/day and alprazolam 0.75 mg/day. Despite exhaustive 
consulting and multiple efforts towards an optimal doctor-
patient relationship, the patient refused to start her treatment, 
even at low doses and despite the offer for more frequent, yet still 
affordable, follow-up visits. Upon inquiring about her refusal, the 
patient expressed significant concerns related to the information 
she came across over the internet and the booklet enclosed in 
the escitalopram box. Regrettably, the patient’s beliefs were 
supported by her husband, who questioned the actual efficacy 
of the antidepressant drug (besides the safety concerns already 
raised by his wife). The patient strongly opposed the prescription 
made by the treating physician, so she ended up taking just 
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alprazolam, a benzodiazepine, to self-medicate her pain. She did 
not inform her psychiatrist about her partial adherence to the 
prescribed drugs. The patient also missed most of the follow-up 
visits, so that the treating clinician had no chance to prevent or 
to foresee her first suicidal attempt, which occurred about three 
months after she initially sought psychiatric consultation.
The patient attempted suicide by jumping out of her home 
window. Such an attempt was averted by her husband, who 
rushed the patient to the E.R. unit of the Teramo public 
hospital (Italy) soon after that. The psychiatrist on duty at the 
hospital confirmed the diagnosis of MDD made by the private 
practice physician, confirming the escitalopram prescription 
(also increasing the dosage up to 20 mg/day), and alprazolam. 
The consultant psychiatrist reassured both the patient and the 
husband and pointed out the risks associated with untreated 
depression, including suicidal behavior, especially after previous 
attempts. The therapist made intense efforts to explain to the 
couple the relevance for balanced evaluations of the efficacy, 
safety and tolerability profile for each drug, and to trust the 
physician irrespective of the advertisement posted elsewhere. 
Since the patient refused admittance to the inpatient unit, she 
was discharged, closely monitored and evaluated every week (free 
consultations offered in the public healthcare system), with the 
specific goal of building up a better patient-doctor relationship 
to finally achieve recovery.
After roughly two months, psychoeducation and most likely 
regular intake of escitalopram, led to substantial remission of 
depression.
Moreover, the patient did not show any adverse effect or 
worsening of suicidal ideation due to antidepressant therapy 
in the long-term period (last evaluation carried on September 
2016). The patient self-reported to regularly take escitalopram 
10 mg/day upon achieved euthymia, joining a mutual aid self-aid 
group run by patients who recovered from depression, being also 
active in arranging meetings and encouraging people to seek help 
and taking the prescribed medications, possibly developing some 
sort of proactive reactive formation during the follow-up visits.
Patient n.2
Mr. S. is a 23-year-old Caucasian man with a three-year history of 
panic disorder (PD). He was a semi-professional football player 
before experiencing his first panic attack on June 2013, while 
driving through into a tunnel. His familial and personal history 
was negative for any psychiatric disorder, including substance 
abuse or suicide. He sought several medical consultations (i.e., 
cardiologist and neurologist) before reaching a psychiatrist who 
prescribed paroxetine gradually up-titrated up to 20 mg/day 
and alprazolam 0.50 mg/day for his newly diagnosed PD. The 
patient took paroxetine only for a few days as he was skeptical 
about its efficacy and concerned about the black box warning on 
antidepressant-related suicide.
Moreover, Mr. S. reported that several internet websites and 
forums he consulted were highly informative about the hazards 
of exposure to antidepressants and the related induction of both 
tolerance to antidepressants and suicide. Similar beliefs were held 
by some of his close peers and friends.
Within the following six months, the patient suffered several 
further panic attacks, refusing to take medication regardless of 
the efforts made by his treating psychiatrist to reassure him. 
As a consequence, the number and the frequency of new panic 
attacks surged within the following months. Intense panic attack 
recurrence occurred roughly ten times a week (usually twice a 
day) when he finally started to take alprazolam (still misreporting 
to his doctor about paroxetine due to the black box warnings and 
the fear to commit any involuntary suicidal behavior).
The patient quickly developed tolerance to alprazolam, ending 
up in abuse of daily doses up to 5mg. When finally dismissed 
by his football team without appeal owing to his now-evident 
addictive behavior towards benzodiazepines, he developed 
clinical depression, while still suffering panic attacks. He was then 
evaluated by another psychiatrist who confirmed the paroxetine 
prescription, which the patient refused to take due to his strong 
concerns about increased risk for suicidality, regardless of the 
additional efforts made by the psychiatrist to reassure and properly 
inform him under careful monitoring over the time. The patient 
did not show up to follow-up visits. Mr. S. attempted to commit 
suicide hanging from his bathroom doorknob when rescued by his 
brother.
The patient was rushed to the E.R. service of a hospital in 
Central Italy, where he was evaluated by a consultant psychiatrist 
who confirmed the diagnosis of MDD with comorbid PD. The 
prescribed therapy included the following: paroxetine (up to 
20 mg/day), progressive down-titration of alprazolam to 3 mg/
day and sodium valproate (500 mg/day). The patient was critical 
about his attempt since his first hospital admission, accepting to 
take the prescribed medications after full disclosure of both the 
pros and cons of antidepressant therapy, at the presence of his 
relatives, who possibly acted as a deterrent for new infringement 
of therapeutic recommendations. Indeed, the patient started 
to take the therapy regularly and, after a couple of weeks, he 
experienced substantial remission of symptoms, achieving 
full symptom remission within two months. Alprazolam and 
valproate were gradually tapered before being stopped in full 
with no inconvenience for the patient. The last observation 
was carried on October 2016, and the patient was entirely 
asymptomatic while taking only paroxetine 20 mg/day without 
reporting any adverse effects, not even hypomania. At that time, 
the patient restarted playing in a football team, also serving as 
a volunteer in an association helping patients with psychiatric 
disorders.
Both patients provided valid informed consent prior to our 
presenting this piece of work.
DISCUSSION
The two case reports briefly presented herein add to the relatively 
scarce evidence available in the literature about the potential 
consequences of over-concern raised by the FDA black-box 
warning on antidepressant and suicide.
The two case reports presented highlight the following: 
i) Misleading interpretations about the black-box warning 
persist after roughly a decade since the FDA 2007 revision. 
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Leisure activity (i.e., sport), stable familial relationships, 
and average education level are not sufficient deterrents. 
Paradoxically, higher education, and chances to access 
informed web resources may backfire. ii) Most psychiatrists 
still face strong stigma and opposition by some patients and 
their relatives, or peers. iii) Adherence and physician trust 
are undermined by the overwhelming information available 
through the media.
Almost every year or so, another pop therapist comes 
along to persuade depressed people that they should soldier 
on with their misery rather than try antidepressants and that 
most antidepressants are either quackery or just harmful 
prescriptions pushes by pharmaceutical companies. While 
well-grounded, evidence-based awareness about the potential 
risk of antidepressant-induced risk for suicide in a minority of 
depressed cases is a necessary reminder, and the FDA needs to 
continue to ensure information on the topic, a severe warning 
may sound like an alarm.
Both cases briefly presented herein raise some issues which 
should deserve a critical appraisal. Among others is the issue 
above of stigma, which is still a significant concern in modern 
clinical psychiatry and relates to deep cultural factors shared 
among different social groups and cultural backgrounds 
(21). Also, adherence is already weak in most severe cases of 
depression, as these are patients who rarely spontaneously seek 
for medical care, not even when experiencing sudden and very 
intense worsening of overall symptomatology (as depicted in 
case n.2). Similarly, polypharmacy and the lack of a multi-
disciplinary approach, as well as a propensity for benzodiazepine 
abuse, are well-known phenomenon that essentially regard full-
threshold bipolar disorder (BD) patients (22, 23). Yet this could 
also be extended to some DSM-IV-defined cases of MDD (24), 
whereas the therapeutic alliance would become crucial especially 
for long-lasting treatments (25).
Both patients exhibited affective temperament traits suggestive of 
cyclothymia, which in turn would point towards a bipolar diathesis 
(26). This is with reference to the plausible demonstrative acts carried 
out by patient n.1, or the intense stress experienced by patient n. 2 in 
response to interpersonal and social rejection. However, none of the 
two patients underwent affective temperament nor sub-threshold 
bipolarity assessment (27, 28).
The lack of use of either the Mood Diagnostic Questionnaire 
or the Hypomania Check-List-32 represents a significant 
issue in our reports, especially considering that local language 
adaptations have been made available at the time of the patients’ 
evaluation (29–31).
Specifically, patient n. 2 showed two signs suggestive of sub-
threshold bipolarity of the otherwise diagnosed DSM-IV MDD: 
lifetime PD and rapid pop-up response on antidepressants (32, 
33) as seldom occurs in DSM-IV-defined full-threshold BD 
with current MDE (34). Yet, there is no FDA recommendation 
about the need to systematically assess sub-threshold bipolarity 
to date.
Although suggestive and relevant from a clinical (6) and a 
methodological standpoint (35), the actual potential impact of 
sub-threshold bipolarity in connection with suicidal ideation 
due to antidepressant exposure in some MDD cases is beyond 
the possibility of the present concise report. Indeed, neither 
of the two patients exhibited overt manic switch or any over 
mixed features within the follow-up period. Nonetheless, both 
cases paradoxically document how neglected sub-threshold 
bipolarity assessment is in the clinical practice, including 
primary care (36).
It is also worth noticing that pivotal pharmaco-epidemiologic 
studies found a relationship between a higher number of sales or 
prescriptions of antidepressants and a lower suicide rate (37–39).
Warnings that antidepressants may increase suicides appear to 
have backfired as suggested by Rihmer (40, 41) and by Isacsson 
and Allner (42), who analyzed a database of 845 suicides in the 
10- to 19-year age group in Sweden within the years of 1992–2003 
(baseline) and 2004–2010 (after the warning), concluding that 
“…the warning, contrary to its intention, may have increased young 
suicides by leaving a number of suicidal young persons without 
treatment with antidepressants.” Moreover, the presence of the 
black box concerning suicidality had a great resonance on several 
internet websites and forums, with dangerous amplification of the 
perceived risk, especially for those who have no real scientific basis, 
as was the case with both patient n. 1 and n. 2. In particular, patient 
n. 2 was overconcerned about the risk of developing tolerance to 
antidepressants, a scenario which albeit infrequent, may inflate 
the rates of recurrence of depression and suicide (33, 43), thus 
prompting further assessment by the FDA (44, 45).
Among other implications, the black box warning issued by 
the FDA could not determine any conclusive causal relationship. 
Depression represents a trans-diagnostic condition, and this is 
also why the antidepressant drug nomenclature seems outdated 
and misleading (because of its disease-targeted approach) in 
contrast to the novel neuroscience-based nomenclature, which 
seems more sound (46).
Milane et al. (47) found an inverse correlation between suicide 
rates and fluoxetine prescriptions (47). Re-analysis of published 
data by Gibbons et al. (48) found that fluoxetine and venlafaxine 
decreased suicidal thoughts and behavior for adults. Once again, this 
may suggest a possible differential developmental neurobiological 
profile among the cases that will be harmed by antidepressants, 
especially during adolescence or young adulthood vs. other cases 
which may benefit. Coupland et al. (49) demonstrated higher rates 
of suicide/suicide attempt/self-harm just after starting/stopping 
antidepressant treatment, concluding that, overall, treatment with 
antidepressant(s) may improve outcomes (49) given that depression 
itself is inherently associated with an increased risk of suicide, 
suicidal behavior, anxiety and pharmaco-phobia overall (50).
Above all, based on the present case reports, we suggest that 
the black box should finally be lifted, at least for adult patients, at 
least until further light can be shed over such an inconclusive and 
vividly debated matter.
We believe that the Hippocrates’s principle “primum non nŏcēre” 
(“first not harm”) should be accepted without any prejudice. In 
other words, while the potential risk of induced suicide caused 
by antidepressants in children or adolescents or adults serves as 
a prompt for careful vigilance, the risk for over-concern among 
clinicians and patients, and the subsequent actual risk for suicidality 
due to the progression of the natural course of MDD, should likewise 
be appropriately counterbalanced.
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The risk of suicide associated with untreated depression or 
anxiety disorder is high and represents a significant public health 
concern (51). As pointed out by Friedman (52), the FDA was 
aware of the need to balance the quantitatively small risk associated 
with antidepressant treatment against related proven benefits, 
yet it expanded the black-box warning issued in 2007 stating that 
depression itself is associated with an increased risk of suicide (52). 
Roughly ten years have passed since the extended warning by the 
FDA and the subsequent alarm from some prescribing clinicians 
over-concerned about regulatory, license or insurance issues, as well 
as by patients or relatives exposed to stigmatization or incorrect 
information (53).
Also, the FDA may have accumulated additional data over 
the past decade, yet not allowed it to be released to the general 
public, potentially affecting the judgment of risk.
Interestingly, in the year 2008, the FDA made an alert about 
antiepileptic drugs (AEDs), stating that they may increase the risk 
of suicide. In that occasion, the scientific advisory committee voted 
against placing a black box warning on AEDs and suicide, although 
there was a significant positive association between AEDs and 
suicidality. The FDA attitude towards the AEDs may be perceived 
as a change in the position of the FDA over time, soliciting revision 
and updating of the black box label warning for antidepressant 
drugs.
The FDA expanded the black box warning already in the year 
2007, stating that depression carries an increased risk of suicide itself. 
Further revision is warranted (54), placing further emphasis on the 
physician-patient interaction and the involvement of the caregivers, 
especially during the initial phase of the antidepressant treatment to 
reduce the risk for emergent suicidal ideation and self-harm.
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